Gilteritinib
Gilteritinib is an anti-cancer drug.
It acts as an inhibitor of AXL receptor tyrosine kinase, hence it is a tyrosine kinase inhibitor.
It was developed by Astellas Pharma.
In April 2018, Astellas filed a new drug application with the Food and Drug Administration for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.
In November 2018, the FDA approved gilteritinib for treatment of adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation as detected by an FDA-approved test. The recommended dose of gilteritinib is 120 mg orally once daily.
Gilteritinib was granted orphan drug status by the U.S. FDA, the European Commission and the Japan Ministry of Health, Labor and Welfare, for some AML patients.
Gilteritinib has been repurposed as a potential antiviral drug as a possible application in the treatment of COVID-19.
